{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Prostate+Carcinoma&page=2", "query": { "condition": "Advanced Prostate Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Prostate+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T06:46:41.553Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00134056", "title": "S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Cancer", "Prostate Cancer" ], "interventions": [ { "name": "atrasentan hydrochloride", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1038, "start_date": "2006-08", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2021-10-27", "last_synced_at": "2026-05-22T06:46:41.553Z", "location_count": 554, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 378 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Fairbanks", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00134056" }, { "nct_id": "NCT06910657", "title": "IDOV-Immune for Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Pancreatic Cancer", "Melanoma", "Ovarian Cancer", "Gastric Cancer", "Esophageal Cancer", "Hepatocellular Carcinoma", "Renal Cell Carcinoma", "Breast Cancer", "Sarcoma", "Bladder Cancer", "Lung Cancer", "Prostate Cancer", "Cervical Cancers", "Head and Neck Cancers", "Adrenal Gland Tumors" ], "interventions": [ { "name": "IDOV-Immune (oncolytic vaccinia virus)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ViroMissile, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2025-08-25", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-05-22T06:46:41.553Z", "location_count": 3, "location_summary": "St Louis, Missouri • Houston, Texas • San Antonio, Texas", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06910657" }, { "nct_id": "NCT04927663", "title": "11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Carcinoma", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8", "Solid Tumor, Adult", "Solid Tumor", "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "11C-YJH08", "type": "DRUG" }, { "name": "Optional Tumor Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Rahul Aggarwal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 2, "start_date": "2021-08-10", "completion_date": "2025-02-28", "has_results": true, "last_update_posted_date": "2025-05-20", "last_synced_at": "2026-05-22T06:46:41.553Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04927663" }, { "nct_id": "NCT00288444", "title": "Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer", "Soft Tissue Sarcoma", "Colorectal Carcinoma", "Breast Cancer", "Prostate Cancer" ], "interventions": [ { "name": "Lonafarnib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 38, "start_date": "2006-01", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2012-12-18", "last_synced_at": "2026-05-22T06:46:41.553Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00288444" }, { "nct_id": "NCT03367819", "title": "Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Isatuximab SAR650984", "type": "DRUG" }, { "name": "Cemiplimab REGN2810", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2018-01-04", "completion_date": "2021-03-10", "has_results": true, "last_update_posted_date": "2022-05-16", "last_synced_at": "2026-05-22T06:46:41.553Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Hackensack, New Jersey + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03367819" }, { "nct_id": "NCT03860272", "title": "Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Angiosarcoma", "Colorectal Cancer Without Liver Metastases", "Endometrial Cancer", "Fibrolamellar Carcinoma", "Non-small-cell Lung Cancer", "Ovarian Cancer", "Prostate Cancer" ], "interventions": [ { "name": "Botensilimab", "type": "DRUG" }, { "name": "Balstilimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agenus Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 499, "start_date": "2019-03-20", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-05-22T06:46:41.553Z", "location_count": 17, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 9 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03860272" }, { "nct_id": "NCT00036075", "title": "Study Using CP-461 to Treat Advanced Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "CP-461", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 25, "start_date": "2001-08", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2011-10-17", "last_synced_at": "2026-05-22T06:46:41.553Z", "location_count": 2, "location_summary": "New York, New York • Seattle, Washington", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00036075" }, { "nct_id": "NCT03829930", "title": "Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Adenocarcinoma" ], "interventions": [ { "name": "Entinostat", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "George Washington University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 6, "start_date": "2019-05-01", "completion_date": "2020-09-01", "has_results": false, "last_update_posted_date": "2021-08-02", "last_synced_at": "2026-05-22T06:46:41.553Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03829930" }, { "nct_id": "NCT07262619", "title": "EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "MSI-H or dMMR Advanced Solid Tumors", "MSI-H/dMMR Gastric Cancer", "MSI-H/dMMR Colorectal Cancer", "MSI-H/dMMR Gastroesophageal-junction Cancer", "Endometrial Cancer", "Mismatch Repair Deficient or MSI-High Solid Tumors" ], "interventions": [ { "name": "EIK1005", "type": "DRUG" }, { "name": "pembrolizumab (KEYTRUDA® )", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eikon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2026-01-20", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-05-22T06:46:41.553Z", "location_count": 3, "location_summary": "Morristown, New Jersey • New York, New York • Houston, Texas", "locations": [ { "city": "Morristown", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07262619" }, { "nct_id": "NCT03493945", "title": "Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer", "Prostate Cancer", "Prostate Neoplasm", "Advanced Solid Tumor", "Solid Tumor", "Non-metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "M7824", "type": "BIOLOGICAL" }, { "name": "N-803", "type": "DRUG" }, { "name": "MVA-BN-Brachyury", "type": "BIOLOGICAL" }, { "name": "FPV-Brachyury", "type": "BIOLOGICAL" }, { "name": "Epacadostat", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Ibuprofen", "type": "DRUG" }, { "name": "Naproxen", "type": "DRUG" }, { "name": "Benadryl", "type": "OTHER" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone scan", "type": "DIAGNOSTIC_TEST" }, { "name": "CT chest, abdomen and pelvis", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 59, "start_date": "2018-05-01", "completion_date": "2024-10-08", "has_results": true, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-05-22T06:46:41.553Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03493945" } ] }